Disparities in capreomycin resistance levels associated with the rrs A1401G mutation in clinical isolates of mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 444-449

  Reeves, Analise Z ^a,c   Campbell, Patricia J ^a,b   Willby, Melisa J ^a   Posey, James E ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BACTERIAL RNA; CAPREOMYCIN; KANAMYCIN; TUBERCULOSTATIC AGENT;

ALLELE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL MUTATION; BACTERIUM ISOLATE; CONTROLLED STUDY; CROSS RESISTANCE; GENETIC ASSOCIATION; HEALTH CARE DISPARITY; MINIMUM INHIBITORY CONCENTRATION; MUTANT; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POINT MUTATION; WILD TYPE; DRUG EFFECTS; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; MUTATION; PROCEDURES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

AMIKACIN; ANTIBIOTICS, ANTITUBERCULAR; CAPREOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; KANAMYCIN; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84920129927     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04438-14     Document Type: Article

References (31)

1. World Health Organization. 2013. Global tuberculosis report 2013. World Health Organization, Geneva, Switzerland.
2. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. 2009. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 4:e6914. http://dx.doi.org/10.1371/journal .pone.0006914.
3. Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM, Hooks DP, Cowan LS, Plikaytis BB, Posey JE. 2011. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 55:2032-2041. http: //dx.doi.org/10.1128/AAC.01550-10.
4. World Health Organization. 2013. The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs. World Health Organization, Geneva, Switzerland.
5. Magnet S, Blanchard JS. 2005. Molecular insights into aminoglycoside action and resistance. Chem Rev 105:477-498. http://dx.doi.org/10.1021 /cr0301088.
6. Johansen SK, Maus CE, Plikaytis BB, Douthwaite S. 2006. Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 2=-Omethylations in 16S and 23S rRNAs. Mol Cell 23:173-182. http://dx.doi .org/10.1016/j.molcel.2006.05.044.
7. Maus CE, Plikaytis BB, Shinnick TM. 2005. Molecular analysis of crossresistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 49:3192-3197. http://dx.doi.org/10.1128/AAC.49.8.3192-3197.2005.
8. Via LE, Cho SN, Hwang S, Bang H, Park SK, Kang HS, Jeon D, Min SY, Oh T, Kim Y, Kim YM, Rajan V, Wong SY, Shamputa IC, Carroll M, Goldfeder L, Lee SA, Holland SM, Eum S, Lee H, Barry CE, III. 2010. Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean patients with drug-resistant tuberculosis. J Clin Microbiol 48:402-411. http://dx.doi.org/10.1128/JCM.01476-09.
9. Georghiou SB, Magana M, Garfein RS, Catanzaro DG, Catanzaro A, Rodwell TC. 2012. Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One 7:e33275. http://dx.doi.org/10.1371 /journal.pone.0033275.
10. Taniguchi H, Chang B, Abe C, Nikaido Y, Mizuguchi Y, Yoshida SI. 1997. Molecular analysis of kanamycin and viomycin resistance in Mycobacterium smegmatis by use of the conjugation system. J Bacteriol 179: 4795-4801.
11. Alangaden GJ, Kreiswirth BN, Aouad A, Khetarpal M, Igno FR, Moghazeh SL, Manavathu EK, Lerner SA. 1998. Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 42:1295-1297.
12. Jnawali HN, Yoo H, Ryoo S, Lee KJ, Kim BJ, Koh WJ, Kim CK, Kim HJ, Park YK. 2013. Molecular genetics of Mycobacterium tuberculosis resistant to aminoglycosides and cyclic peptide capreomycin antibiotics in Korea. World J Microbiol Biotechnol 29:975-982. http://dx.doi.org/10 .1007/s11274-013-1256-x.
13. NCCLS. 2003. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard M24-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
14. Jugheli L, Bzekalava N, de Rijk P, Fissette K, Portaels F, Rigouts L. 2009. High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob Agents Chemother 53:5064-5068. http://dx.doi.org/10.1128/AAC.00851-09.
15. Jureen P, Angeby K, Sturegard E, Chryssanthou E, Giske CG, Werngren J, Nordvall M, Johansson A, Kahlmeter G, Hoffner S, Schon T. 2010. Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections. J Clin Microbiol 48:1853-1858. http://dx.doi.org/10.1128/JCM.00240-10.
16. Kruuner A, Jureen P, Levina K, Ghebremichael S, Hoffner S. 2003. Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 47:2971-2973. http://dx.doi.org/10.1128/AAC.47.9.2971-2973.2003.
17. Rodwell TC, Valafar F, Douglas J, Qian L, Garfein RS, Chawla A, Torres J, Zadorozhny V, Kim MS, Hoshide M, Catanzaro D, Jackson L, Lin G, Desmond E, Rodrigues C, Eisenach K, Victor TC, Ismail N, Crudu V, Gler MT, Catanzaro A. 2014. Predicting extensively drug-resistant Mycobacterium tuberculosis phenotypes with genetic mutations. J Clin Microbiol 52:781-789. http://dx.doi.org/10.1128/JCM.02701-13.
18. Sirgel FA, Tait M, Warren RM, Streicher EM, Bottger EC, van Helden PD, Gey van Pittius NC, Coetzee G, Hoosain EY, Chabula-Nxiweni M, Hayes C, Victor TC, Trollip A. 2012. Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis. Microb Drug Resist 18:193-197. http://dx.doi.org/10 .1089/mdr.2011.0063.
19. Lin SY, Rodwell TC, Victor TC, Rider EC, Pham L, Catanzaro A, Desmond EP. 2014. Pyrosequencing for rapid detection of extensively drug-resistant Mycobacterium tuberculosis in clinical isolates and clinical specimens. J Clin Microbiol 52:475-482. http://dx.doi.org/10.1128/JCM .01821-13.
20. Angeby K, Jureen P, Kahlmeter G, Hoffner SE, Schon T. 2012. Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. Bull World Health Organ 90:693-698. http: //dx.doi.org/10.2471/BLT.11.096644.
21. Fenner L, Egger M, Bodmer T, Altpeter E, Zwahlen M, Jaton K, Pfyffer GE, Borrell S, Dubuis O, Bruderer T, Siegrist HH, Furrer H, Calmy A, Fehr J, Stalder JM, Ninet B, Bottger EC, Gagneux S. 2012. Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 56:3047-3053. http://dx.doi .org/10.1128/AAC.06460-11.
22. van Kessel JC, Hatfull GF. 2008. Efficient point mutagenesis in mycobacteria using single-stranded DNA recombineering: characterization of antimycobacterial drug targets. Mol Microbiol 67:1094-1107. http://dx .doi.org/10.1111/j.1365-2958.2008.06109.x.
23. Shcherbakov D, Akbergenov R, Matt T, Sander P, Andersson DI, Bottger EC. 2010. Directed mutagenesis of Mycobacterium smegmatis 16S rRNA to reconstruct the in vivo evolution of aminoglycoside resistance in Mycobacterium tuberculosis. Mol Microbiol 77:830-830. http: //dx.doi.org/10.1111/j.1365-2958.2010.07218.x.
24. Andersson DI. 2006. The biological cost of mutational antibiotic resistance: any practical conclusions? Curr Opin Microbiol 9:461-465. http: //dx.doi.org/10.1016/j.mib.2006.07.002.
25. Bottger EC, Springer B. 2008. Tuberculosis: drug resistance, fitness, and strategies for global control. Eur J Pediatr 167:141-148. http://dx.doi.org /10.1007/s00431-007-0606-9.
26. Blaschitz M, Hasanacevic D, Hufnagl P, Hasenberger P, Pecavar V, Meidlinger L, Konrad M, Allerberger F, Indra A. 2011. Real-time PCR for single-nucleotide polymorphism detection in the 16S rRNA gene as an indicator for extensive drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 66:1243-1246. http://dx.doi.org/10.1093/jac/dkr070.
27. Evans J, Segal H. 2010. Novel multiplex allele-specific PCR assays for the detection of resistance to second-line drugs in Mycobacterium tuberculosis. J Antimicrob Chemother 65:897-900. http://dx.doi.org/10.1093/jac /dkq047.
28. Feuerriegel S, Cox HS, Zarkua N, Karimovich HA, Braker K, Rusch-Gerdes S, Niemann S. 2009. Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment. Antimicrob Agents Chemother 53: 3353-3356. http://dx.doi.org/10.1128/AAC.00050-09.
29. van Kessel JC, Hatfull GF. 2008. Mycobacterial recombineering. Methods Mol Biol 435:203-215. http://dx.doi.org/10.1007/978-1-59745-232-8-15.
30. de Vos M, Muller B, Borrell S, Black PA, van Helden PD, Warren RM, Gagneux S, Victor TC. 2013. Putative compensatory mutations in the rpoC gene of rifampin-resistant Mycobacterium tuberculosis are associated with ongoing transmission. Antimicrob Agents Chemother 57:827-832. http://dx.doi.org/10.1128/AAC.01541-12.
31. Baquero F. 2013. Epigenetics, epistasis and epidemics. Evol Med Public Health 2013:86-88. http://dx.doi.org/10.1093/emph/eot009.